SiGRP78-modified MSC-derived exosomes bound to sorafenib, targeted GRP78 in HCC cells and inhibited HCC cell growth, invasion and metastasis in vivo and in vitro, and reversed the resistance of cancer cells to sorafenib [98]. The gene discussed is HSPA5; the disease is cancer.